MiSalud Health, a prominent digital health platform offering affordable, same-day bilingual telehealth consultations (Spanish/English) in the U.S. and Mexico, has announced the appointment of co-founder Bismarck Lepe as CEO. Lepe steps into the role as Cindy Blanco transitions to lead…
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR® AI platform, announced today the enrollment and dosing of the first patient in Taiwan for its Phase 2 HARMONIC™ clinical trial. The trial is…
Four new studies on the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these, preliminary data will be shared exploring the potential of the BCI test to identify postmenopausal women…
Celltrion announced today that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is now approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), as well as for…
Intelliguard, a leading provider of RFID-enabled medication management and data-intelligence solutions, has announced a strategic partnership with Codonics, a global leader in healthcare technology focused on patient safety. This collaboration integrates Intelliguard’s Mira Care Station with Codonics’ Safe Label System…
DNAnexus, Inc., a leader in precision health data platforms, and Panomics, Inc., specializing in AI-powered omics data management and discovery for biopharma, have announced a strategic collaboration. This partnership will deliver biopharma organizations a comprehensive solution for multi-omics data management…
MaaT Pharma will host a KOL webinar on December 17th, 2024, to discuss the data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) – Register here. Key Results: MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company specializing in…
Genentech, a member of the Roche Group, today announced five-year follow-up data from the pivotal Phase III POLARIX study. The study evaluated Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with untreated diffuse…
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has presented promising results from its Phase 2 waveLINE-007 trial at the 66th American Society of Hematology (ASH) Annual Meeting. The trial evaluated zilovertamab vedotin, an investigational antibody-drug…
ReAlta Life Sciences, Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, announced promising preclinical data for its lead asset, RLS-0071 (pegtarazimod), in acute Graft-versus-Host Disease (aGVHD). These findings will…
Genmab A/S has shared new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) for treating relapsed or refractory (R/R) follicular lymphoma (FL). The study demonstrated an…
Orca Bio, a late-stage biotechnology company focused on transforming patient care through high-precision cell therapy, presented clinical findings today at the 66th American Society of Hematology (ASH) Annual Meeting. The data highlights the use of Orca-Q, its investigational second-generation allogeneic…